At the European annual biotech conference Biotech Atelier 2021 (https://biotech-atelier.com/) BiomeDx presented its current research giving an introduction on its myBioma product and the current state of BiomeOne. Interesting facts on the microbial diversity trend of Europeans during the COVID-19 pandemic and the future of fecal microbiota transplants were discussed.
The conference was a great opportunity to meet and discuss with international microbiome researchers on topics of cancer treatment, aging and nutrigenetics.
Dr. Nikolaus Gasche from BiomeDx
BiomeOne describe the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker, that can be used for any tumor type.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
Agenda: https://biotech-atelier.com/ba2021/agenda/
Follow us on LinkedIn
